Maitake Mushroom

A real Phase I/II human immune trial -- alongside much weaker case-series claims

Real safety/immune-marker trial

Regression claims come from a weaker case series

Important: These statements have not been evaluated by the FDA. This information is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any supplement.

Not a cancer treatment: The most-cited "regression in 60%+ of patients" figure comes from a small, non-randomized 2002 case series without a placebo control -- not a controlled trial. No human research shows Maitake shrinks tumors or extends survival. If you are exploring it alongside cancer treatment, discuss it with your oncologist first -- it is not a substitute for conventional care and may interact with chemotherapy or immunosuppressive drugs.

Overview

Maitake (Grifola frondosa) is a polypore mushroom native to Japan, North America, and Europe, traditionally called "the dancing mushroom." Its signature studied compound is the D-fraction, a purified beta-glucan-protein complex distinct from the PSK/PSP fraction that makes Turkey Tail well known, or the beta-glucans studied in Reishi and Shiitake.

Maitake research is a genuine mixed bag worth being upfront about. On one end, a real Phase I/II trial run at a major U.S. cancer center found Maitake extract safe in breast cancer patients and documented dose-dependent immune-cell activation. On the other end, the dramatic "cancer regression" statistics that circulate in supplement marketing trace back to a small, non-randomized, non-placebo-controlled case series from 2002 -- a much lower tier of evidence that shouldn't be confused with a clinical trial.

Potential Benefits

Immune Cell Activation (Human Data)

A Phase I/II trial in postmenopausal breast cancer patients found Maitake liquid extract was safe with no dose-limiting toxicity, and observed measurable changes in immune cell activity at higher doses over 3 weeks.

D-Fraction Mechanism

Preclinical research shows the D-fraction beta-glucan activates macrophages, T cells, and natural killer (NK) cells -- the plausible biological basis for the immune effects seen in early human trials.

Case-Series Observations (Weaker Evidence)

A 2002 non-randomized case series of 165 patients reported symptom improvement in a majority of liver, breast, and lung cancer cases alongside chemotherapy -- an interesting signal, but without a control group it cannot establish that Maitake caused the improvement.

General Immune Wellness

Like other medicinal mushrooms, Maitake is most reasonably framed as general immune-system support based on preclinical mechanism data, not as a treatment for any specific condition.

Typical Dosage

Standard Daily Dose

500–1,000mg

Standardized extract; human trials used liquid extract dosed by body weight

What to Look For on the Label

D-fraction or beta-glucan percentage

Whole mushroom powder without a standardized fraction has far less research behind it

Pro Tips

Don't confuse the marketing-friendly "60%+ regression" statistic with a controlled trial result
Immune-modulating supplements can interact with immunosuppressants and chemotherapy -- talk to your oncologist first
If you're already taking Turkey Tail or Reishi, adding Maitake is redundant unless you have a specific reason
Take with food to reduce the mild GI upset some users report

Research Snapshot

A 2009 Phase I/II trial led by Memorial Sloan Kettering Cancer Center enrolled 34 postmenopausal breast cancer patients, free of disease after initial treatment, and gave them oral Maitake liquid extract at escalating doses (0.1 to 5 mg/kg twice daily) for 3 weeks. The primary endpoints were safety and tolerability -- no dose-limiting toxicity was observed, and immune parameters showed dose-dependent changes, with both immune-enhancing and immune-suppressing effects appearing at different dose levels. This is a genuinely useful safety and mechanism study, but it was not designed or powered to test whether Maitake affects cancer outcomes.

Source: Deng et al., Journal of Cancer Research and Clinical Oncology (2009)

How Maitake Compares

Ingredient	Best For	Key Difference
Maitake Mushroom	Immune Support	D-fraction; strongest data is a safety/immune-marker trial, not an efficacy RCT
Turkey Tail Mushroom	Adjunct Cancer Support	PSK is an approved prescription adjunct drug in Japan -- the most clinically established mushroom fraction
Reishi Mushroom	Immune Modulation, Sleep	Broader traditional-use history; some human trials on sleep and fatigue
Lion's Mane	Cognitive Support	Targets nerve growth factor pathways -- a different mechanism entirely

These are the most common comparisons our customers ask about in-store.

Popular Stacks with Maitake Mushroom

Immune Foundation

Maitake + Vitamin D3 + Zinc

Broad-spectrum immune support

Mushroom Blend

Maitake + Reishi + Turkey Tail

Multiple beta-glucan fractions together

Antioxidant Support

Maitake + Vitamin C + NAC

General wellness combination

Frequently Asked Questions

How is Maitake different from Turkey Tail, Reishi, or Lion's Mane?

Each medicinal mushroom is studied for a different beta-glucan fraction and different use case. Turkey Tail's PSK/PSP fraction has the most established adjunct-cancer-therapy history (approved as a prescription drug in Japan). Reishi is studied mainly for immune modulation and sleep. Lion's Mane targets nerve growth factor and cognition. Maitake's signature compound is the D-fraction, studied specifically for its effect on immune cell activity in cancer patients -- it's a related but distinct research tradition, not interchangeable with the others.

Can Maitake mushroom treat or cure cancer?

No. The available human research looked at immune markers and safety, or came from small non-randomized case series -- not controlled trials proving Maitake shrinks tumors or extends survival. Any use alongside cancer treatment should be discussed with an oncologist first; it is not a substitute for conventional care.

Is the human evidence for Maitake strong?

It's mixed. A real Phase I/II trial at a major cancer center found Maitake extract safe and observed measurable immune-cell activation at higher doses in breast cancer patients. But the widely cited claim of "cancer regression in 60%+ of patients" comes from a small, non-randomized 2002 case series without a placebo control -- a much weaker form of evidence that shouldn't be read as proof of anticancer effect.

Sources & References

1. Deng, G., Lin, H., Seidman, A., et al. (2009). A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of Cancer Research and Clinical Oncology, 135(9), 1215–1221.

2. Kodama, N., Komuta, K., & Nanba, H. (2002). Can maitake MD-fraction aid cancer patients? Alternative Medicine Review, 7(3), 236–239. (Non-randomized case series, not a controlled trial -- cited here to show the actual quality of evidence behind commonly repeated statistics.)

All references are peer-reviewed studies; evidence quality and study design are noted honestly where relevant.